Edition:
United States

Catalyst Pharmaceuticals Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

1.24USD
13 Jan 2017
Change (% chg)

$0.06 (+5.08%)
Prev Close
$1.18
Open
$1.17
Day's High
$1.25
Day's Low
$1.15
Volume
1,007,835
Avg. Vol
871,242
52-wk High
$2.25
52-wk Low
$0.51

Latest Key Developments (Source: Significant Developments)

Catalyst Pharmaceutical Partners Inc. prices public offering of common stock
Wednesday, 4 Feb 2015 09:00am EST 

Catalyst Pharmaceutical Partners Inc:Pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at an offering price of $3.25 per share.In connection with the offering, Catalyst has also granted the underwriters 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any.Net proceeds from the sale of the shares by Catalyst after underwriting discounts and commissions and other offering expenses are expected to be about $30.1 mln.Catalyst plans to use the net proceeds from the offering to pay milestone payments due on final approval of an NDA for Firdapse; to pay pre commercialization and other expenses required to launch Firdapse.Also uses to fund future clinical studies of Firdapse for other indications, to the extent that such additional studies are required; to fund future clinical and nonclinical studies of CPP-115; and for general corporate purposes.The offering is subject to customary closing conditions and is expected to close on Feb. 9.Piper Jaffray & Co. is acting as the sole lead book-running manager and SunTrust Robinson Humphrey is acting as the passive book-running manager with respect to this offering.Further, Roth Capital Partners and H.C. Wainwright & Co. are acting as the lead co-manager and co-manager, respectively.  Full Article

Catalyst Pharmaceutical Partners Inc announces commencement of public offering of common stock
Tuesday, 3 Feb 2015 04:40pm EST 

Catalyst Pharmaceutical Partners Inc:Intends to offer shares of its common stock in a public offering.Also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any.Plans to use the net proceeds from the offering to pay milestone payments due on final approval of an NDA for Firdapse, to pay pre-commercialization and other expenses required to launch Firdapse.Also uses to fund future clinical studies of Firdapse for other indications, to the extent that such additional studies are required.Also to fund future clinical and nonclinical studies of CPP-115 and for general corporate purposes.Piper Jaffray & Co. is acting as the sole lead book-running manager and SunTrust Robinson Humphrey is acting as the passive book-running manager.  Full Article

BRIEF-Catalyst Pharmaceuticals announces Q3 2016 financial results

* Catalyst Pharmaceuticals-continues to believe currently available resources will be sufficient to complete development of Firdapse